Table 2.

Indirect comparison of overall survival

HR of OS (95% CI)
GEM
2.03 (1.63–2.54) *	GEM-NAB
2.19 (1.77–2.71) *	1.08 (0.92–1.25)	FOLFIRINOX
2.29 (1.55–3.40) *	1.13 (0.78–1.63)	1.05 (0.75–1.47)	mFOLFIRINOX

Abbreviation: HR: hazard ratio; OS: overall survival; CI: confidence interval; GEM: gemcitabine; GEM-NAB: Gemcitabine plus nab-paclitaxel; FOLFIRINOX: the combination of 5-fluorouracil, oxaliplatin, and irinotecan; mFOLFIRINOX: at least one of the drugs was reduced and/or the removal of 5-FU bolus in FOLFIRINOX

Notes: Comparisons between treatments were read from left to right, and the estimate (HR) with 95% CI for a given comparison was read in the intersection of two treatments. The value of estimates higher than 1 indicated that column-defining treatment had better efficacy

* Denotes p-value < 0.05